

August 14, 2025

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd. Exchange
Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 14th August, 2025

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (14/08/2025):

1. Financial Results:

Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Period ended 30/06/2025 in the format specified under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), together with a copy of the Limited Review Reports of M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai for your records and for uploading in your website. The aforesaid Unaudited Financial Results are also uploaded on the Company's website www.fischermv.com

An extract of the aforesaid Unaudited Financial Results, in the manner prescribed under the SEBI Listing Regulations, is annexed herewith in **Annexure-1** and the same will be published in English and Telugu newspapers within the time stipulated.

2. 32nd Annual General Meeting:

The 32nd Annual General Meeting ('AGM') of the Members of the Company will be held on Monday, 29th September 2025 through video conferencing or other audio-visual means.

3. Considered & approved the appointment of M/s Nuren Lodaya & Associates Practicing Company Secretary as Scrutinizer of the Annual General Meeting, to scrutinize the e-voting and remote e-voting process in a fair and transparent manner;

4. Closure of Register of Members:

Please note that the share transfer books of the Company will remain closed 23/09/2025 (Tuesday) to 29/09/2025 (Monday) (both days inclusive).

5. Recommended the Appointment of M/s Nuren Lodaya & Associates Practicing Company Secretary (M No. A60128; COP No. 24248) as Secretarial Auditors of the Company for the term of Five years from the conclusion of 32nd Annual General Meeting.
6. Noted the Resignation of the Dr. Jacob Thomas, Independent Director (DIN: 10639814) with effect from the closing hours of 14th August 2025. Details as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure 2**

The Board Meeting commenced at 12.45 PM (IST) and concluded at 1.30 PM (IST)

Please take on record.

Thanking You,

Yours Truly,

Thanking You,

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



ARAVINDKUMAR V

COMPANY SECRETARY AND COMPLIANCE OFFICER



FISCHER MEDICAL VENTURES LIMITED
(formerly known as Fischer Chemic Limited)
CIN: L86900AP1993PLC118162

Regd Off: No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Visakhapatnam, Andhra Pradesh, India, 530044

Corp off: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006, India

Email: cs@fischermv.com | Website: www.fischermv.com

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30.06.2025 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs

SL NO	PARTICULARS	STANDALONE					CONSOLIDATED				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025	31.03.2024	30.06.2025	31.03.2025	30.06.2024	31.03.2025	31.03.2024
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)
I	Revenue From Operations	454.23	521.97	-	521.97	1,152.83	2,344.47	4,917.42	1,012.07	11,069.87	2,098.13
II	Other Income	80.40	64.94	112.23	345.70	75.05	746.64	14.87	74.17	149.20	50.11
III	Total Income (I + II)	534.63	586.90	112.23	867.67	1,227.88	3,091.11	4,932.29	1,086.25	11,219.07	2,148.25
IV	Expenses										
	Cost Of Materials Consumed	-	-	-	-	-	-	-	-	-	1,573.80
	Purchase of Traded Assets	318.59	454.56	-	461.06	1,072.36	758.01	3472.30	1,751.84	9,528.18	7.87
	Changes in inventories of finished goods, by-products and work in progress	-	-	-	(6.50)	-	496.32	458.75	(890.39)	(369.22)	63.74
	Employee Benefits Expense	41.75	4.74	2.53	12.84	5.50	315.77	93.58	39.31	258.13	38.10
	Direct Expenses	-	-	-	-	-	22.09	-	-	-	-
	Depreciation and Amortisation Expenses	8.16	9.86	0.05	12.72	0.08	76.97	51.03	27.72	163.28	18.21
	Finance Costs	130.88	12.41	-	13.17	1.58	66.99	22.63	12.50	46.68	6.76
	Other Expenses	56.81	218.48	8.70	278.30	94.49	326.27	642.46	128.95	1,321.11	228.66
	Total Expenses	556.19	700.05	11.28	771.59	1,174.01	2,062.43	4,740.75	1,069.92	10,948.15	1,937.14
V	Profit / (Loss) Before Exceptional Items & Tax (III - IV)	(21.56)	(113.15)	100.95	96.08	53.87	1,028.68	191.54	16.32	270.92	211.11
VI	Share of profit/(loss) of Associates	-	-	-	-	-	0.11	(1.53)	(3.61)	(13.29)	-
VI	Exceptional Items	-	-	-	-	-	(11.26)	(8.79)	(5.11)	(35.36)	-
VII	Profit / (Loss) Before Tax (V - VI)	(21.56)	(113.15)	100.95	96.08	53.87	1,017.53	181.22	7.60	222.27	211.11
VIII	Tax Expense										
	Current Tax	-	2.00	(17.00)	(52.00)	(3.00)	(441.62)	(59.35)	(17.00)	(107.95)	(3.00)
	Deferred Tax (Asset) / Liability	(39.38)	27.50	(0.01)	27.64	(10.59)	(75.09)	9.35	(2.32)	11.87	(24.33)
	Tax pertaining to Previous year	-	(5.40)	-	(5.40)	-	-	-	-	(5.40)	-
IX	Profit / (Loss) For The Period From Continuing Operations (VII - VIII)	(60.94)	(89.05)	83.94	66.32	40.28	500.82	131.22	(11.71)	120.79	183.78
X	Profit / (Loss) From Discontinued Operations	-	-	-	-	-	-	-	-	-	-
XI	Tax Expense Of Discontinued Operations	-	-	-	-	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinued Operations After Tax (X - XI)	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) For The Period (IX + XII)	(60.94)	(89.05)	83.94	66.32	40.28	500.82	131.22	(11.71)	120.79	183.78
XIV	Items That Will Not Be Reclassified To Profit / (Loss)										
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	-	-	-	-	-	-	(0.78)	-	(0.78)	-
	(ii) Income Tax Relating On Above	-	-	-	-	-	-	-	-	-	-
	(iii) Equity Instruments Through Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income - Total	-	-	-	-	-	-	(0.78)	-	(0.78)	-
XV	Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))	(60.94)	(89.05)	83.94	66.32	40.28	500.82	130.44	(11.71)	120.01	183.78
XVI	Paid Up Equity Share Capital (Face Value Re.1/-)	6,485.15	6,380.15	5,350.00	6,380.15	6,485.15	6,485.15	6,380.15	5,350.00	6,380.15	6,485.15
XVII	Other Equity				24,166.26					24,350.14	
XVIII	Earnings Per Share (EPS) From Continuing Operations & Discontinued Operations (In Rs.)										
	Basic	(0.09)	(0.06)	0.16	0.05	0.36	0.09	(0.05)	0.65	0.22	1.65
	Diluted	(0.09)	(0.06)	0.15	0.04	0.36	0.09	(0.05)	0.64	0.22	1.08

Notes:

- These unaudited consolidated financial results relate to Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) (the 'Company'), and its Subsidiaries (together the 'Group'), and Associates are prepared by applying Ind AS 110 - "Consolidated Financial Statements",
- The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 14th August 2025
- Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification.
- The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company.
- The Statutory Auditor of the Company reviewed the above Standalone and Consolidated Financial Results for the quarter ended 30.06.2025 and the Limited review Report with an unmodified opinion was placed before the Board.

// BY ORDER OF THE BOARD //

For and on behalf of the Board
Fischer Medical Ventures Limited
(Formerly known as Fischer Chemic Limited)



[Signature]
Chairman & Managing Director
DIN : 03137661

Date: 14.08.2025

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to date of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To

The Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Company') for the quarter ended **30th June 2025** and year to date result for the period from **1st April 2025 to 30th June 2025** being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') , and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI {Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Opinion is not modified in respect of these matters.

For Bilimoria Mehta & Co.

Chartered Accountants
Firm Reg. No. 101490W

**Aakash
Himanshu
Mehta** Digitally signed by
Aakash Himanshu
Mehta
Date: 2025.08.14
12:30:16 +05'30'

CA Aakash Mehta

Partner
Membership no. 165824
UDIN: 25165824BMILB5613
Place: Mumbai
Date: 14-08-2025

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30th June 2025 and consolidated year to date results for the period 1 April 2025, to 30th June 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1 /44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.
5. Based on our review conducted and procedures performed and upon consideration of the review reports of other auditors below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying interim financial results of subsidiaries included in the Statement, whose financial information reflects total assets of Rs. 41,539.12 Lakhs as at 30th June 2025, and year-to-date total revenues of Rs 3091.11 lakhs and year-to-date total comprehensive income of Rs 500.82 lakhs, as considered in the Statement. The independent auditor's reports on interim financial results and other financial information of these entities have been furnished to us by management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditors.

Further, these subsidiaries and an associate, which are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

For Bilimoria Mehta & Co,
Chartered Accountants
ICAI Firm Registration No.: 101490W

Aakash
Himanshu
u Mehta

Digitally signed
by Aakash
Himanshu Mehta
Date: 2025.08.14
12:29:30 +05'30'

CA Aakash Mehta
Partner
Membership No: 165824
UDIN: 25165824BMILC4689
Place: Mumbai
Date: 14-08-2025

ANNEXURE-1

List of Entities included in the statement:

<u>Sr no</u>	<u>Particulars</u>	<u>Stakes</u>	<u>Status</u>
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary
2	Time Medical Philippines (Subsidiary of Time Medical International Ventures (India) Private Limited)	75%	Subsidiary
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of (Time Medical)
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of (Time Medical)
5	Flynncare HealthCare Innovations Private Limited	100%	Subsidiary of Fischer Medical Ventures Limited
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer Medical Ventures Limited
7	Fischer Hospitality Sdn. Bdn.	60%	Subsidiary of Fischer Medical Ventures Limited
8	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited
9	FMV HealthCare PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited
10	FMV Global Innovation PTE Ltd	100%	Subsidiary of Fischer Medical Ventures Limited

ANNEXURE – 2

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

<i>Name</i>	<i>DR. JACOB THOMAS</i>
<i>DIN</i>	<i>10639814</i>
<i>Reason for Change</i>	<i>Resignation as the Director of the Company with effect from closure of Business hours on 14th August 2025 due to personal reasons and no other material reasons</i>
<i>Date of cessation</i>	<i>Closure of Business hours on 14th August 2025</i>
<i>Term of appointment/reappointment;</i>	<i>Not Applicable</i>
<i>Brief profile (in case of appointment)</i>	<i>Not Applicable</i>
<i>Disclosure of relationships between Directors</i>	<i>No relation with Directors</i>
<i>Other Directorships / Memberships (in listed entities in case of resignation of Independent director)</i>	<i>Nil</i>
<i>The independent director shall, along with the detailed reasons, also provide a confirmation that there is no other material reasons other than those provided.</i>	<i>Dr. Jacob Thomas has confirmed that there are no material reasons for his resignation other than those mentioned in his resignation letter</i>
